[1] FRY D W. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy： progression from reversible to irreversible inhibitors[J] . Pharmacol Ther，1999. 82. 207. [2] YADEN Y. SLIWKOWSKI MX. Untangling the ErbB signaling network[J] . Nat Rev Mol Cell Biol，2001，2(2)：127-37. [3] SMAILL JB. REWCASTLE GW. Loo JA. Et al. Tyrosine kinase inhibitors：Irreversible inhibitors of the epidermal growth factor recaptor：4-(phenylamino) quinazoline-and 4-(phenylamino) pyrido[3. 2-d] pyramidine-6-acrylamides bearing additional solubilizing functions[J] . J Med Chem，2000. 43[7] ：1380-1397. [4] KLAPPER LN. KIRSCHBAUM MH. SELA M. Et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor recaptors[J] . Adv Cancer Res，2000，77：25-79. [5] CHO HS. LEAHY DJ. Structure of the extracellular region of HER3 reveals an interdomain tether[J] . Sci，2002，297(5585)：1330-1333. [6] MENDROLA J M. BERGER M B. King M C et al. The single transmembrane domains of erbB recaptors self-associate in cell membranes[J] . J Biol Chem，2002，277(7)：4704-4712. [7] HIRARATA A. OGAWA S. KOMETNI T. et al. ZD1839(iressa) induce antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase[J] . Cancer Res，2002，62(9)：2554-2560. [8] GHOSH S. LIU XP. ZHENG Y. Et al. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents[J] . Current Cancer Drug Targets，2001，1(2)：129-140. [9] FRY D. W. Mechanism of action of erbB tyrosine kinase inhibitors[J] . Exp Cell Res，2003，10；284(1)：131-139. [10] WARD W H. COOK P N. SLATER A M. Et al. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism. Structure-based searching and discovery of a potent inhibitor[J] . Biochem Pharmacol，1994，17；48(4)：659-666. [11] YARDEN Y. The EGFR family and its ligands in human cancer：signaling mechanisms and therapeutic opportunities[J] . Eur J Ccncer，2001，37(Supp 14)：3-8. [12] JANNMAAT ML. Giaccone G. Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [J] . Oncologist，2003，8(18)：576-586. [13] HERBST R S. GIACCONE G. SCHILLER J H. Et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer： a phase Ⅲtrial 2 intact 2[J] . J Clin Oncol，2004，22(9)：785-794. [14] TSOU H R. MAMUYA N. JOHNSON B D. Et al. 6-substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor recaptor(EGFR) andhuman epidermal growth factor recaptor(Her-2) tyrosine kinases with enhanced antitumor activeity[J] . J Med Chem，2001，44(17)：2719-2734. [15] GIACCONE G. HERBST RS. MANEGOLD C. Et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer： a phase Ⅲtrial 2 intact 1[J] . J Clin Oncol，2004，22(9)：777-784. [16] ADJEI A A. Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy[J] . Drugs Fut，2001，26(11)：1087-1092. [17] GORDANA Y. CRAUFORAL J. Activation of tyrosine kinases in cancer[J] . Oncologist，2003，8(6)：531-538. [18] JOSE B L. HAMMOND L A. HER-targeted tyrosine-kinases inhibitors[J] . Oncology，2002，63(Supp 1)：6-16. [19] HIDALGO M. SIU L L. Phase Ⅰ andpharmacyologic study of OSI-774. An epidermal growth factor recaptor tyrosine kinase inhibitor. In patients with advanced solid malignancies[J] . J Clin Oncol，2001，19(13)：3267-3279. [20] DONG Q G. Epidermal growth factor receptor family and molecular targeting therapy of lung . Cancer [J] . Cancer(肿瘤)，2004，24（2）：93-95. [21] RATAIN M J. GEORGE C M. JANISCH L. Et al. PhaseⅠ trial of elotinib (OSI-774) in combination with gemcitabine(G) and cisplatin(P) in patients with advanced solid tumors[J] . Proc Am Soc Clin Oncol，2002，21(12S)：2115-2116. [22] GATZEMEIER U. PLUAZNSKA A. Results of a phase Ⅲtrial of erlotinib(OSI-774) combined with cisplatin and gemcitabine(GC) chem. Otherapy in advanced non-small cell lung cancer(NSCLC)[J] . Proc Am Soc Clin Oncol，2004，22(14s)：619-621. [23] HERBST R S. PRAGER D. TRIBUTE-A phase trial of erlotinib(OSI-774) combined with caroplatin and paclitaxel(CP) chem. Otherapy in advanced non－small cell lung cancer(NSCLC)[J] . Proc Am Soc Clin Oncol，2004，22(14s)：619-623. [24] RYAN A J. ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity[J] . Br J Cancer，2005，92（Suppl 1）：6-13. [25] HEYMACH J V. ZD6474-clinical experience to date[J] . Br J Cancer，2005，92（Suppl 1）：14-20. [26] ZHOU H. KIM Y S. PELETIER A. Et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR and HER2-overexpessing breast cancer cell line prolixferation. Radiosensitization. And resistance[J] . Int J radiat Oncol Biol Phys，2004，58(2)：344-352. [27] DACCI C. CARIELLO A. MAIOLI P. Et al. Prognostic and predictive valve of intratumoral microvessels density in operable nonsmall cell lung cancer[J] . Lung Cancer，1999，24(2)：81-88. [28] KRIS M G. HERBST R. RISCHIN D. Et al. Objective regressions in nonsmall cell lung cancer patients treated in phase Ⅰtrials of oral AD1839(Iressa). A selective tyrosine kinase. Inhibitor that blocks the epidermal growth factor receptor(EGFR)[J] . Lung Cancer，2000，29(Suppl 1)：72-77. [29] LASKINA J J. SANDLER A B. Epidermal growth factor receptor： a promising target in solid tumours[J] . Cancer Treat Rev，2004，30(1)：1-17. [30] CIARIDELLO F. CAPUTO R. DAMIANO V. Et al. Antitumor effects of ZD6474. A small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor. With additional activity against epidermal growth factor receptor tyrosine kinase[J] . Clin Cancer Res，2003，9(4)：1546-1556. [31] DANCEY J. Epidermal growth factor recaptor inhibitors in clinical development[J] . Int J Radiat Oncol Biol Phys，2004，58(3)：1003-1007. [32] MICHAEL A G. BOCK C，FERGUSON L R. Evidence for epidermal growth factor receptor enhanced chemsensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033[J] . Anticancer Drugs，2001，12(7)：683-690. [33] CAMPOS S, HAMID O, SEIDEN M V. et al. Multicenter. Randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer[J] . J Clin Oncol，2005，20；23(24)：5597-5604. [34] REENBERGER L M. DISCAFANI C. WANG Y F. Et al. 388 EKB-569：a new irreversible inhibitor of epidermal growth factor recaptor tyrosine kinase for treatment of cancer[J] . Clin Cancer Res，2000，6：388-389. [35] DAVID W F. Inhibition of the epidermal growth factor recaptor family of tyrosine kinases as an approach to cancer chemotherapy： progression from reversible to irreversible inhibitors[J] . Pharmacol Ther，1999，82(2-3)：207-218.